NCT04184921 2026-02-03
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
Clinical Trials
3 trialsNCT03543683 2025-02-27
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT02123849 2018-08-29
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
National Cancer Institute (NCI)
Phase 2 Completed